DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents

被引：391
作者：
O'Connor, J. P. B.
Jackson, A.
Parker, G. J. M.
Jayson, G. C.
机构：
[1] Univ Manchester, Imaging Sci & Biomed Engn, Manchester M13 9PT, Lancs, England
[2] Christie Hosp, Canc Res UK Dept Med Oncol, Manchester M20 4BX, Lancs, England
来源：
BRITISH JOURNAL OF CANCER | 2007年 / 96卷 / 02期
基金：
英国医学研究理事会;
关键词：
angiogenesis inhibitors; biomarkers; clinical trials; dynamic contrast; enhanced magnetic resonance imaging; image analysis;
D O I：
10.1038/sj.bjc.6603515
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is now frequently used in early clinical trial assessment of antiangiogenic and vascular disrupting compounds. Evidence of drug efficacy and dose-dependent response has been demonstrated with some angiogenesis inhibitors. This review highlights the critical issues that influence T-1-weighted DCE-MRI data acquisition and analysis, identifies important areas for future development and reviews the clinical trial findings to date.
引用
收藏
页码：189 / 195
页数：7
相关论文
共 43 条
[1]   Cellular abnormalities of blood vessels as targets in cancer [J].
Baluk, P ;
Hashizume, H ;
McDonald, DM .
CURRENT OPINION IN GENETICS & DEVELOPMENT, 2005, 15 (01) :102-111
[2]   Comparison of the performance of tracer kinetic model-driven registration for dynamic contrast enhanced MRI using different models of contrast enhancement [J].
Buonaccorsi, Giovanni A. ;
Roberts, Caleb ;
Cheung, Sue ;
Watson, Yvonne ;
O'Connor, James P. B. ;
Davies, Karen ;
Jackson, Alan ;
Jayson, Gordon C. ;
Parker, Geoff J. M. .
ACADEMIC RADIOLOGY, 2006, 13 (09) :1112-1123
[3]  
Conrad C, 2004, J CLIN ONCOL, V22, p110S
[4]  
Dowlati A, 2002, CANCER RES, V62, P3408
[5]  
Drevs J, 2005, J CLIN ONCOL, V23, p192S
[6]   Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily [J].
Eder, JP ;
Supko, JG ;
Clark, JW ;
Puchalski, TA ;
Garcia-Carbonero, R ;
Ryan, DP ;
Shulman, LN ;
Proper, J ;
Kirvan, M ;
Rattner, B ;
Connors, S ;
Keogan, MT ;
Janicek, MJ ;
Fogler, WE ;
Schnipper, L ;
Kinchla, N ;
Sidor, C ;
Phillips, E ;
Folkman, J ;
Kufe, DW .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (18) :3772-3784
[7]   Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126 [J].
Evelhoch, JL ;
LoRusso, PM ;
He, ZQ ;
DelProposto, Z ;
Polin, L ;
Corbett, TH ;
Langmuir, P ;
Wheeler, C ;
Stone, A ;
Leadbetter, J ;
Ryan, AJ ;
Blakey, DC ;
Waterton, JC .
CLINICAL CANCER RESEARCH, 2004, 10 (11) :3650-3657
[8]   Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging [J].
Galbraith, SM ;
Maxwell, RJ ;
Lodge, MA ;
Tozer, GM ;
Wilson, J ;
Taylor, NJ ;
Stirling, JJ ;
Sena, L ;
Padhani, AR ;
Rustin, GJS .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (15) :2831-2842
[9]   Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging [J].
Galbraith, SM ;
Rustin, GJS ;
Lodge, MA ;
Taylor, NJ ;
Stirling, JJ ;
Jameson, M ;
Thompson, P ;
Hough, D ;
Gumbrell, L ;
Padhani, AR .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (18) :3826-3840
[10]  
HECHT JR, 2005, J CLIN ONCOL, V23, P3
12345